A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Clinical trial NCT06769152 · RECRUITING
Trial details
- NCT number
- NCT06769152
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-20
- Primary completion
- 2026-12-31
- Enrollment
- 190
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.